New HPV vaccine enters first human tests
NCT ID NCT05208710
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new vaccine called PANHPVAX in 45 healthy adults aged 18-45. The vaccine targets a part of the HPV virus (L2 antigen) to potentially protect against multiple HPV types. The main goal is to check safety and how well the body's immune system responds to different doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Department of Clinical Pharmacology and Pharmacoepidemiology
RECRUITINGHeidelberg, 69120, Germany
Contact Email: •••••@•••••
Contact Email: •••••@•••••